|Product Name||Human EGFR/HER1/ErbB1 ELISA Kit|
|Customs Name||Human EGFR/HER1/ErbB1 ELISA Kit|
|Assay Type||Sandwich ELISA|
|Suitable Sample Type||serum, plasma, cell culture supernates|
|Format||96-well strip plate|
|Storage||4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)|
|Sample Volume||100 μl (prediluted)|
|Standard Curve Range||78.13 - 5000 pg/ml|
|Spike Recovery Range||87 % - 119 %|
|Mean Spike Recovery||1.06|
|CV of Intra plate||2.2 % - 3.5 %|
|CV of Inter plate||2.3 % - 4.4 %|
|Components||96-well polystyrene microplate coated with a monoclonal antibody against EGFR
Human EGFR Standard, lyophilized
EGFR Detect Antibody
Assay Buffer (10×)
Washing Buffer (20×)
|Describtion||This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human EGFR. The Human EGFR/HER1/ErbB1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.
The epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, a type I transmembrane glycoprotein. It exists on the cell surface and is activated by binding of its specific ligands, including EGF and TGF-α. EGFR signaling plays a crucial role in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR homo- or hetero- dimerization, initiates subsequent tyrosine autophosphorylation and various downstream pathways (MAPK, PI3K/PKB and STAT).
Activation of the receptor is important for the innate immune response in human skin. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme. Aberrant EGFR signaling has been implicated in psoriasis, eczema and atherosclerosis. Currently, EGFR was proposed as a target for cancer therapy.